Advertisement
Screener

BeyondSpring Inc. (BYSI) Operating Lease, Expense

2.8 / 5 stars · 68/120 Roast Me

BeyondSpring Inc. Operating Lease, Expense

BeyondSpring Inc. (BYSI) reported Operating Lease, Expense of $281.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingLeaseExpense · last filed 2026-03-25

  • BeyondSpring Inc. operating lease, expense for the quarter ending 2019-12-31 was $221.00K, a 4.74% decline year-over-year.
  • BeyondSpring Inc. operating lease, expense for the quarter ending 2019-09-30 was $198.00K, a 86.79% increase year-over-year.
  • BeyondSpring Inc. operating lease, expense for the quarter ending 2019-06-30 was $195.00K, a 37.32% increase year-over-year.
  • BeyondSpring Inc. operating lease, expense for the quarter ending 2019-03-31 was $202.00K, a 197.06% increase year-over-year.
  • BeyondSpring Inc. operating lease, expense for fiscal 2025 was $281.00K, a 5.24% increase from fiscal 2024.
  • BeyondSpring Inc. operating lease, expense for fiscal 2024 was $267.00K, a 61.64% decline from fiscal 2023.
  • BeyondSpring Inc. operating lease, expense for fiscal 2023 was $696.00K.
Period endOperating Lease, Expense 3 monthOperating Lease, Expense 6 monthOperating Lease, Expense 9 monthOperating Lease, Expense 12 month
2025-12-31$281.00K
10-K · filed 2026-03-25
2024-12-31$267.00K
10-K · filed 2026-03-25
2023-12-31$696.00K
10-K · filed 2025-03-27
2022-12-31$1.11M
20-F · filed 2023-04-18
2021-12-31$725.00K
20-F · filed 2023-04-18
2020-12-31$878.00K
20-F · filed 2023-04-18
2019-12-31$221.00K
derived: 20-F 12 month − 6-K 9 month · filed 2022-04-14
$419.00K
derived: sum of 2 quarters · filed 2022-04-14
$614.00K
derived: sum of 3 quarters · filed 2022-04-14
$816.00K
20-F · filed 2022-04-14
2019-09-30$198.00K
6-K · filed 2019-12-18
$393.00K
derived: sum of 2 quarters · filed 2019-12-18
$595.00K
6-K · filed 2019-12-18
$827.00K
derived: sum of 4 quarters · filed 2021-04-30
2019-06-30$195.00K
6-K · filed 2019-09-18
$397.00K
6-K · filed 2019-09-18
$629.00K
derived: sum of 3 quarters · filed 2021-04-30
$735.00K
derived: sum of 4 quarters · filed 2021-04-30
2019-03-31$202.00K
6-K · filed 2019-07-10
$434.00K
derived: sum of 2 quarters · filed 2021-04-30
$540.00K
derived: sum of 3 quarters · filed 2021-04-30
$682.00K
derived: sum of 4 quarters · filed 2021-04-30
2018-12-31$232.00K
derived: 20-F 12 month − 6-K 9 month · filed 2021-04-30
$338.00K
derived: sum of 2 quarters · filed 2021-04-30
$480.00K
derived: sum of 3 quarters · filed 2021-04-30
$548.00K
20-F · filed 2021-04-30
2018-09-30$106.00K
6-K · filed 2019-12-18
$248.00K
derived: sum of 2 quarters · filed 2019-12-18
$316.00K
6-K · filed 2019-12-18
2018-06-30$142.00K
6-K · filed 2019-09-18
$210.00K
6-K · filed 2019-09-18
2018-03-31$68.00K
6-K · filed 2019-07-10
2017-12-31$200.00K
20-F · filed 2020-04-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30